Neurology Alert – November 1, 2009
November 1, 2009
View Issues
-
Strengthening the Case for Early Parkinson's Treatment
In a delayed-start trial of rasagiline in early Parkinson's disease, 1 mg rasagiline daily met all three predetermined endpoints consistent with disease modification. However, a dose of 2 mg daily did not meet all endpoints, complicating interpretation. -
Diagnostic Utility of Muscle Biopsies in the Age of Molecular Genetics
Muscle biopsy still remains an important test for determining correct diagnosis and treatment of patients with suspected muscle disease. -
New Agents for Stroke Prevention in Atrial Fibrillation-The Proven and the Potential
An oral direct thrombin inhibitor, dabigatran, prevents ischemic strokes in patients with atrial fibrillation, with fewer hemorrhagic strokes as compared to warfarin. -
A 2nd-generation Anti-epileptic Agent for Childhood Occipital Epilepsy
This open label trial reports on the long-term efficacy and tolerability of levetiracetam in children with late onset childhood occipital epilepsy. -
New Genetic Clues to Alzheimer's Disease Risk
Recent breakthroughs in genetic research will bring us closer to being able to diagnose an individual's risk of developing late-onset sporadic Alzheimer's disease. -
Bell's Palsy: Meta-analysis Supports Adding Anti-viral Medication to Steroid Therapy
Review of available literature suggests that combination therapy of Bell's palsy with both steroids and anti-virals results in the best outcome. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Depression and pregnancy, new vaccine recommendations from the CDC, cortico-steroids and/or antivirals for Bell's palsy, rasagiline and Parkinson's disease, and FDA Actions.